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The peroxisome proliferator-activated receptor-α (PPARα) plays a key role in lipid metabolism and energy combustion. Chronic
activation of PPARα in rodents leads to the development of hepatocellular carcinomas. The ability of PPARα to induce expression
of its target genes depends on Mediator, an evolutionarily conserved complex of cofactors and, in particular, the subunit 1 (Med1)
of this complex. Here, we report the identiﬁcation and characterization of PPARα-interacting cofactor (PRIC)-295 (PRIC295),
a novel coactivator protein, and show that it interacts with the Med1 and Med24 subunits of the Mediator complex. PRIC295
contains 10 LXXLL signature motifs that facilitate nuclear receptor binding and interacts with PPARα and ﬁve other members of
thenuclearreceptorsuperfamilyinaligand-dependentmanner.PRIC295enhancesthetransactivationfunctionofPPARα,PP ARγ,
and ERα. These data demonstrate that PRIC295 interacts with nuclear receptors such as PPARα and functions as a transcription
coactivator under in vitro conditions and may play an important role in mediating the eﬀects in vivo as a member of the PRIC
complex with Med1 and Med24.
1.Introduction
Lipid metabolism in mammals is a complex process regu-
lated by diverse factors including the members of the nuclear
receptor subfamily known as peroxisome proliferator-
activated receptors (PPARs). There are three isoforms of
PPARknownasPPARα,PP ARβ/δ,andPP ARγ [1–3].PPARα,
the initial isoform identiﬁed, is centrally involved in the
pleiotropic responses induced in rat and mouse liver by
treatment with peroxisome proliferators [4–7]. Peroxisome
proliferators are structurally diverse chemicals and include
compounds such as cloﬁbrate, bezaﬁbrate, nafenopin, and
others along with phthalate ester plasticizers, certain her-
bicides, pesticides, industrial solvents, and leukotriene D4
receptor antagonists [8, 9]. The pleiotropic responses
induced following treatment with a peroxisome proliferator
include the lowering of serum lipids, the proliferation of
hepatic peroxisomes, and the coordinated induction of fatty
acid oxidation genes involved in the mitochondrial and
peroxisomalβ-oxidation,andmicrosomalω-oxidationpath-
ways [10]. Additionally, rats and mice chronically exposed
to peroxisome proliferators develop a high incidence of
hepatocellular carcinomas even though these compounds
are nongenotoxic and considered a paradigm for epigenetic
carcinogenesis [5, 6, 11]. PPARα also exerts a signiﬁcant role
in the process of inﬂammation [12–15]. All these responses,
including the development of hepatocellular carcinomas, are
receptor mediated and achieved through selective activation
of PPARα [16–18].
PPARs heterodimerize with retinoid X receptor-α
(RXRα) and bind to peroxisome proliferator response ele-
ments (PPREs) present in the promoter region of target
genes[19–22].Intheabsenceofcognateligand,transcription
of target genes is repressed by corepressor proteins such as
silencing mediator of retinoic acid and thyroid hormone
receptors(SMRT)[23],nuclearreceptorcorepressor(NCoR)
[24, 25], and receptor interacting protein 140 (RIP140)
[26] bound to the PPAR-RXR heterodimers. Upon ligand
binding, PPARs undergo a conformational change causing
thedissociationofcorepressorproteinsandthenallowingfor2 PPAR Research
the orchestrated recruitment of coactivator proteins [27, 28].
These coactivator proteins enhance transcription through
various means including histone acetyltransferase activity,
methyltransferaseactivity or mediating the interaction of the
activated PPAR-RXR heterodimer with the basal transcrip-
tion machinery of the cell [29–35].
Coactivators and coactivator-associated proteins known
to be involved in PPARα-mediated transactivation include
three members of the SRC (steroid receptor coactivator)/
p160 family of proteins [29, 32, 36], CBP (CREB-bind-
ing protein)/p300 [35, 37, 38], PBP (PPARγ-binding pro-
tein)/MED1/TRAP220/DRIP205 [30, 39–45], PRIP/NCoA6/
ASC2/RAP250/TRBP/NRC [46–50], PIMT/NCoA6IP [31],
CARM1[51], PRIC285 [33], PRIC320/CHD9/CReMM [34,
52],PGC-1α[53],PGC-1β,andothers[54,55].Eachofthese
coactivator proteins contains one or more conserved LXXLL
(L = leucine, X = any amino acid) motifs which are neces-
saryfortheinteraction withtheactivation function-2 (AF-2)
domain present at the C-terminal end of a nuclear receptor
[56]. Although several cofactors have been shown to interact
with PPARs and function as transcriptional regulators under
in vitro conditions, there is limited data on the in vivo func-
tions of these molecules in PPAR-regulated target gene tran-
scription. To date, deletion of Med1 in liver has been shown
to abrogate the ability of PPARα to activate transcription of
targetgenesaswellasblockotherpleiotropiceﬀectsofrecep-
tor activation including liver regeneration and the develop-
ment of hepatocellular carcinoma [57]. Furthermore, Med1
deletion also aﬀects PPARγ-regulated adipogenesis in mouse
embryonic ﬁbroblasts and the adipogenic steatosis induced
by PPARγ overexpression in liver [58, 59]. Med1 was ﬁrst
cloned using PPARγ as bait in the yeast two-hybrid system
andsubsequentlydetectedinthePPARα-interactingcofactor
(PRIC) complex of approximately 25 proteins isolated from
rat liver nuclear extracts [30, 33]. The identities of proteins
in the PRIC complex [33] revealed several coactivators pre-
viously identiﬁed in yeast two-hybrid screens such as Med1
[30], CBP [35], SRC-1 [29], Med24/TRAP100 [60], PIMT
[31],andPGC-1[53].ThePRICcomplexalsoincludedsome
novel proteins including PRIC285 and others [33]. Subse-
quently, this approach was modiﬁed to use ciproﬁbrate, a
synthetic PPARα agonist, to pull down a complex of proteins
fromratnuclearextractandthisresultedintheidentiﬁcation
of PRIC320/CHD9 and some other high molecular weight
proteins [34]. In this study, we present data to show that
one of the hitherto uncharacterized high molecular weight
proteins, designated PRIC295, contains 10 LXXLL coactiva-
tor motifs and interacts with PPARα in a ligand-dependent
manner. PRIC295 signiﬁcantly enhances the transcriptional
activity of PPARα in vitro. We further demonstrate that
PRIC295 interacts with the Med1 and Med24 subunits of
the Mediator complex suggesting that PRIC295 may be
important for nuclear receptor signaling in vivo.
2.MaterialsandMethods
2.1. Preparation of Liver Nuclear Extracts and Ciproﬁbrate-
Sepharose Beads for Aﬃnity Pulldown. Liver tissue was har-
vestedfrom5maleF-344ratssacriﬁced1hourafteranintra-
gastric dose of ciproﬁbrate (250mg/kg body weight). Nuclei
were isolated and extract prepared as described elsewhere
[33, 34]. Ciproﬁbrate was immobilized on AH-Sepharose
4B by carbodiimide reaction as previously described [61].
Animals were housed under a 12 hour light/12 hour dark
cycle and maintained in individual cages with standard
rodent chow and water ad libitum. All animal procedures
employed in this study were reviewed and approved by the
Institutional Animal Care and Use Committee (IACUC) at
Northwestern University.
2.2. Aﬃnity Pulldown and Matrix-Assisted Laser Desorption/
Ionization-TimeofFlight. Ciproﬁbrate-sepharosebeadswere
blocked with 1% fatty-acid free bovine serum albumin and
washed with buﬀer containing 0.5% NaCl. Nuclear extract
(∼10mg protein) was allowed to interact with Sepharose
beads with immobilized ciproﬁbrate overnight at 4◦C. After
washing, bound proteins were eluted from the beads by
boiling and resolved by SDS-PAGE on a 3%–8% Tris-
acetategelor4%–20%acrylamidegelasdescribedpreviously
[34]. Gels were stained with silver nitrate to visualize
the resolved proteins and selected bands were cut and
processed for matrix-assisted laser desorption/ionization-
time of ﬂight (MALDI-TOF) analysis using a Voyager DE
Pro at the IMSERC Laboratory at Northwestern University.
Observed peaks were identiﬁed by the use of MS-FIT
(Protein Prospector, University of California, San Francisco).
To isolate PRIC295 interacting proteins, nuclear extracts
were allowed to interact with GST-ΔPRIC295840–1815 (F2)
protein and the bound proteins were subjected to MALDI-
TOF analysis.
2.3. PRIC295 Cloning and Plasmid Constructs. The human
full-length cDNA (KIAA0219) was purchased from the
Kazusa DNA Research Institute, Chiba, Japan. Full-length
expression vectors were made by restriction digestion of
the cDNA and ligation into the pcDNA3.1(+) expression
vector (Invitrogen). Smaller fragments of the cDNA were
ampliﬁed using the high ﬁdelity rTth polymerase (Applied
Biosystems) and ligated into pcDNA3.1(+), pGEX-5X-
1 (GE Healthcare), or pM (Clontech) vectors at the
designated sites to give the plasmids pcDNA-ΔPRIC2951–915
(Fragment1—F1), pcDNA-ΔPRIC295840–1815 (F2), and
pcDNA-ΔPRIC2951740–2671 (F3). These fragments were
also ligated into pGEX-5X-1 and pM. All ﬁnal vectors
were conﬁrmed by sequencing at the Genomics Core
Facility at Northwestern University. In vitro translated
proteins were made using the TnT T7 quick-coupled
transcription/translation kit from Promega according to
the manufacturer’s protocol and radiolabeled with L-35S-
methionine (Perkin Elmer). Other plasmids including
pGEX-PPARα, pCMX-PPARα, pGEX-PPARγ, pCMX-
PPARγ, pGEX-ERα, pcDNA-ERα, pGEX-CAR, pGEX-TRα,
pGEX-RXRα, pCMX-RXRα, CMV-RL, pGL3-3xPPRE-LUC,
PGL3-3xERE-LUC, GST-Med1, and cloned fragments of
Med1 fused to GST have all been previously described
[30, 33, 62].PPAR Research 3
2.4. Northern Blotting and Quantitative Real-Time PCR.
Northern blotting for human PRIC295 mRNA expression
was performed using a multiple tissue blot purchased from
Clontech and the 3
 -terminal 1kb of the PRIC295 cDNA as
a probe. Total RNA for quantitative PCR was isolated using
TRIzol reagent (Invitrogen) according to the manufacturer’s
instructions. Quantitative PCR was done using an ABI 7300
(Applied Biosystems). Samples were tested in triplicate and
normalized with 18S ribosomal RNA. Speciﬁc PCR products
were measured by melting curve analysis and relative gene
expression changes were measured using the comparative CT
method, X = 2−ΔΔCT. PRIC295 qPCR primers were designed
from exons 27 and 28.
2.5. GST-Pulldown with PRIC295 and Nuclear Receptors.
GST and GST-fusion proteins were puriﬁed using glu-
tathione sepharose 4B beads (GE Healthcare) and incu-
bated with in vitro synthesized PRIC295 labeled with 35S-
methionine (or fragments of PRIC295). Binding was allowed
to take place on a gentle shaker at 4◦C for 2 hours, then
bound protein was washed, eluted, and resolved by SDS-
PAGE and analyzed by autoradiography as described earlier
[30, 46]. Quantiﬁcation of binding was performed using
ImageJ software available from the NIH.
2.6. Transactivation Assays. The ability of PRIC295 to
enhance transcriptional activation mediated by PPARα,
PPARγ,o rE Rα wasmeasured by transfecting HeLa cells with
appropriate plasmids using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s protocol. Plasmids used in
these assays were pCMX-PPARα, pCMX-PPARγ,p c D N A -
ERα, pCMX-RXRα, pGL3-3xPPRE-Luc, pGL3-3xERE-Luc,
and pcDNA3.1-PRIC295. Experiments were conducted in
triplicate and luciferase expression was assessed using
the dual-luciferase reporter assay system from Promega
according to the manufacturer’s protocol. Ligands used in
these experiments (Wy-14,643 for PPARα, rosiglitazone for
PPARγ, and 17-β-estradiol for ERα)w e r ea d d e da tac o n -
centration of 100μM. Transcriptional activity of PRIC295
was further examined by transfecting HeLa cells with pM-
ΔPRIC2951–915 (F1), pM-ΔPRIC295840–1815 (F2), or pM-
ΔPRIC2951740–2671 (F3) which express chimeric proteins
containing fused fragments of PRIC295 with the DNA-
binding domain (aa 1–147) of the yeast Gal4 transcription
factor [63]. These cells were also transfected with the Gal4-
TK-Luc plasmid containing the c-terminal portion of the
Gal4 protein and the thymidine kinase promoter upstream
of the luciferase reporter gene. The ability of chimeric Gal4-
PRIC295 proteins to activate transcription of the luciferase
reportergenewasanalyzedbycomparisontocellstransfected
with Gal4-TK-luc and empty pM vector [64].
2.7. Immunoﬂuorescence, Immunoblotting, and Coimmuno-
precipitation. HeLa cancer cells were transfected with
pCMX-PPARα and pcDNA-PRIC295-3xFLAG using lipo-
fectamine 2000 reagent. Cells were ﬁxed 48 hours post-
transfection with 4% paraformaldehyde for 20 minutes and
stained with anti-PPARα (Santa Cruz Biotechnology Inc.—
sc-9000) and anti-FLAG monoclonal antibody M2 (Sigma).
Fluorescence microscopy and digital image photographs
were obtained using a Nikon Eclipse E600 microscope
equipped with a Spot RT slider digital camera and image
analysissoftware(DiagnosticInstruments).Immunoblotting
was performed to ascertain the presence of PPARα,M e d 1 ,
or Med24/TRAP100 in the PRIC complex of proteins
isolated using ciproﬁbrate-Sepharose and proteins that bind
PRIC295 in the GST-pulldown assay. For coimmunopre-
cipitation, HeLa cells were transfected with pcDNA3.1-
PRIC295-3xFLAG and pCMX-PPARα expression vectors
as previously described. Nuclear extract was made and
interacting proteins were puriﬁed using resin covalently
bound with the anti-FLAG M2 antibody (Sigma). Proteins
were subjected to SDS-PAGE, then immunoblotted using
anti-FLAG, anti-Med1 (Santa Cruz Biotechnology, Inc.—sc-
5334), or anti-PPARα.
2.8. Statistical Analysis. Statistical signiﬁcance of the diﬀer-
encebetweentransfectedgroupsofcellsusedintheluciferase
assays were calculated by one-tailed Student’s t-test using the
available functions in Microsoft Excel 2007
3. Results and Discussion
3.1. Identiﬁcation of PRIC295. To identify rat liver proteins
that interact with peroxisome proliferators we initially used
an aﬃnity chromatography approach that involved ciproﬁ-
brate immobilized on AH-Sepharose 4B by carbodiimide
reaction [61]. This procedure resulted in the isolation of
peroxisome proliferator-binding proteins that ranged in
apparent Mr of 31,000–79,000 [61], but they remained
uncharacterized due to the limited availability and appli-
cability at that time of MALDI-TOF technology [65]. The
general availability of MALDI-TOF mass spectrographic
technology in recent years enabled the analysis of liver
nuclear proteins that bind to GST-fused full-length PPARα
[33],ortoAH-Sepharose-ciproﬁbrateaﬃnitymatrix[34].In
the present study, we describe the identiﬁcation of a member
of the PRIC complex from ciproﬁbrate-bound proteins
(Figure 1(a)) which has been designated as PRIC295 based
on molecular mass. Mass spectrographic analysis of one of
the high molecular weight protein bands revealed several
peptide fragments that matched the human KIAA0219
protein (accession number D86973, reference sequence
NM 006836) (Figure 1(b)). Human PRIC295 shares 94%
homology with the rat and 93% homology with the mouse
orthologues. Other proteins identiﬁed by MALDI-TOF in
the PRIC complex include PRIC285, CREB-binding protein
(helicase CBP), PRIC250, and thyroid receptor-interacting
protein 230 (TRIP230) (Figure 1(b)). In this complex, we
also identiﬁed previously known PPARα cofactor proteins
that include PRIC285 and PRIC320 (data not shown).
3.2.MolecularCharacterizationofPRIC295. Thegeneencod-
ing PRIC295 is located on human chromosome 12q23.24
and consists of 58 exons. The nucleotide sequence data4 PPAR Research
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Protein Peptide sequences m/z Accession no.
PRIC295
ISSAGCLGELCAFLTEEELSAVLQQCLLADVSGIDWMVR 4383.139
D86973
QIGSVIRNPEILALAPVLLDALTDPSR 2871.631
ETVLRGLMELHMVLPAPDTDEK 2494.269
YSSDVQEMILSSATADR 1872.865
ENVNSLLPVFEEFLK 1777.938
PRIC285 EALEKPFTVIQGPPGTGKTIVGLHIVFWFHK 3446.899 Q9BYK8 HSRLFWVQIVLWRQGFYYPLGIVR 3033.673
CBP KLDTGQYQEPWQYVDDVWLMFNNAWLYNRK 3820.822 Q92793 FLTLARDKHWEFSSLR 2192.125
PRIC250 SVFYLLMKMFVTSSHLQLKSLTK 2701.483 AB011111 FQEQSQLLYLLDVVRNGIR 2291.251
TRIP230 ISSTSHTQDVVYLQQQLQAYAMEREKVFAVLNEK 3954.007 Q15643
VENLVDQLNKSQESNVSIQK 2272.179
(b)
Figure 1: PRIC295 in ciproﬁbrate bound protein complex. (a) Ciproﬁbrate-binding protein complex isolated from rat liver nuclear extracts
analyzed on a 3%–8% Tris-acetate silver stained gel. Lane 1 marker; lane 2 BP, binding proteins. Selected high molecular weight bands
(arrows) were excised from the gel and digested with trypsin. MALDI-TOF analysis was conducted on the marked bands yielding peptide-
matching protein identities, in descending order from highest molecular weight to lowest, of PRIC295, PRIC285, CBP, PRIC250, and
TRIP230. (b) Mass spectrometric and limited sequence analysis data of proteins identiﬁed by MALDI-TOF with their associated peptide
fragment sequences, m/z ratios and corresponding accession numbers.
for PRIC295 are available in the Third Party Annota-
tion Section of the DDBJ/EMBL/GenBank databases under
the accession number TPA: BK006575. The 8,666bp long
transcript has an open reading frame of 8013bp that
encodes a 2,671 aa protein of approximately 295kDa (acces-
sion number NP 006827.1). PRIC295 contains 10 LXXLL
coactivator motifs located at aa L1,465–469; L2,1160–1164;
L3,1461–1465; L4,1499–1503; L5,1596–1600; L6,1839–1843;
L7,1926–1930; L8,2045–2049; L9,2330–2334; L10,2594–2598
(Figure 2(a)). The LXXLL motifs are signiﬁcant in coactiva-
tor and activator (receptor) interactions. In PRIC295 these
motifs are evolutionarily conserved across many diﬀerent
species (Figure 2(b)). Sequences ﬂanking these conserved
LXXLL motifs have also been shown to be inﬂuential in
determining the speciﬁcity of the interaction between coacti-
vatorsandactivators.ThreeoftheLXXLLmotifs,namely,L2,
L7,a n dL 10, present in PRIC295 possess a conserved proline
in the -2 position relative to the ﬁrst leucine of the LXXLL
motif (Figure 2(b)). The presence of proline at this position
is similar to the biologically important LXXLL motifs known
to interact with PPARα such as those found in Med1 [30].
In addition to LXXLL motifs, the PRIC295 sequence
also reveals the presence of 24 HEAT repeats (see
Table 1 in Supplementary Material available online at
doi:10.1155/2010/173907) which may play a role in protein-
protein interactions as well as energy production and con-
version (NCBI—Conserved Domain Database—COG1413)
(Figure 2(a))[ 66]. HEAT repeat domains are composed of
approximately 50 hydrophobic and charged amino acids
conserved at particular positions within the motif [67].
These motifs are believed to be important in mediating
protein-protein interactions though the exact mechanism byPPAR Research 5
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Figure 2: PRIC295 structural features. (a) Schematic representation of the PRIC295 protein to indicate the locations of LXXLL motifs in
red color and HEAT repeat domains in purple color. (b) Alignment of the orthologous PRIC295 genomic sequences of selected species at the
loci of all 10 of the LXXLL motifs contained in the human PRIC295 protein. LXXLLs are numbered L1 to L10 beginning from the N-terminal
region: L1aa465–469; L2aa1160–1164; L3aa 1461–1465; L4aa1499–1503; L5aa1596–1600; L6aa1839–1843; L7aa1926–1930; L8aa2045–2049;
L9aa2330–2334; L10aa2594–2598. The model organism to which each sequence corresponds is indicated at the left side of the sequence. The
location of conserved proline at—2 of L2,L 7, and L10 are indicated using an arrow.
which this occurs is not clear. The presence of HEAT repeats
in PRIC295 places it in a class of HEAT repeat proteins
known to be involved in gene transcription and translation,
but also have other functions [67]. It is possible that the
HEAT repeats in PRIC295 may be important in mediating
interactions between diﬀerent transcription cofactors within
the PRIC complex.
3.3. Tissue Distribution of PRIC295 Transcripts. Northern
blot analysis revealed that the PRIC295 mRNA transcript
is 8.5kb in length and is expressed in many diﬀerent
human tissues with the highest expression observed in brain,
heart, skeletal muscle, and placenta (Figure 3(a)). In thymus,
spleen, liver, and small intestine PRIC295 expression was
evident whereas in lung and colon the transcript was barely
detectable. The expression of PRIC295 in diﬀerent mouse
tissues was evaluated by qPCR and the data show that it
is expressed robustly in testes, white adipose tissue, brain,
heart, and kidney (Figure 3(b)). Embryonic expression of
PRIC295 mRNA in the mouse was also evaluated using
the qPCR approach and the data suggest higher levels of
expression during developmental stages E15.5 and E16.5. By
E18.5theexpressionlevelwaslow(SupplementaryFigure1).
In situ hybridization data for PRIC295 mRNA localization
during various developmental stages in the mouse should
provide clues about the expression in tissues at diﬀerent
developmental stages.
3.4. Interaction of PRIC295 with Nuclear Receptors. Inter-
actions between PRIC295 and PPARα and some other
members of the nuclear receptor superfamily were analyzed
by GST-pulldown assays. These were performed using6 PPAR Research
(
K
b
)
4.4
7.5
9.5
Human
PRIC295
(∼ 8.5Kb)
B
r
a
i
n
H
e
a
r
t
S
k
e
l
e
t
a
l
m
u
s
c
l
e
C
o
l
o
n
T
h
y
m
u
s
S
p
l
e
e
n
K
i
d
n
e
y
L
i
v
e
r
S
m
a
l
l
i
n
t
e
s
t
i
n
e
P
l
a
c
e
n
t
a
L
u
n
g
L
e
u
k
o
c
y
t
e
(a)
0
5
10
15
20
25
30
35
×10−4
R
e
l
a
t
i
v
e
m
R
N
A
e
x
p
r
e
s
s
i
o
n
B
r
a
i
n
H
e
a
r
t
S
k
.
M
u
s
.
I
n
t
e
s
t
i
n
e
S
p
l
e
e
n
K
i
d
n
e
y
L
i
v
e
r
L
u
n
g
P
a
n
c
.
T
e
s
t
e
s
B
A
T
W
A
T
Mouse
(b)
Figure 3: Expression of PRIC295 in human and mouse tissues.
(a) Northern blot analysis of PRIC295 mRNA expression using
a human multiple tissue blot (Clontech). Blot contains 2μgo f
polyA RNA in each lane from tissues indicated. PRIC295 transcript
(∼8.5kb) is expressed in nearly all tissues. (b) Quantitative PCR
data showing the expression of PRIC295 mRNA in several diﬀerent
mouse tissues. Primers were designed to amplify from the exon 27-
28regionofthecDNAsequence.Sampleswerenormalizedwith18S
RNA. RNA from 5 diﬀerent C57B6/J males was pooled and samples
were run in triplicate. Standard deviations are shown.
bacterially-expressed GST-fusion nuclear receptor proteins
and in vitro translated pcDNA-PRIC295 (Figure 4(a)). Full-
length PRIC295 bound in vitro to PPARα,P P A R γ,R X R α,
CAR, ERα,a n dT R α and addition of receptor speciﬁc ligand
(10μM to 100μM) enhanced this binding (Figure 4(a);
Supplementary Figure 2). Ligands used for each receptor
were pirinixic acid (Wy-14,643) for PPARα, rosiglitazone
for PPARγ, 9-cis-retinoic acid for RXRα, TCPOBOP for
CAR, 17-β-estradiol for ERα, and triiodothyronine (T3)
for TRα. PRIC295 did not bind to GST alone, as expected
(Figure 4(a)).
To further investigate which region of PRIC295 protein
might be involved in receptor interactions, additional GST-
pulldown assays were undertaken using the GST-fusion
receptor proteins and in vitro translated PRIC295 fragments
designated ΔPRIC2951–915 (F1), ΔPRIC295840–1815 (F2), and
ΔPRIC2951740–2671 (F3) (Figure 4(b)). Fragment F1 contains
1L X X L L( L 1), fragment 2 contains 4 LXXLLs (L2–L5),
and fragment 3 contains 5 LXXLLs (L6–L10)( Figure 2(a)).
The fragment ΔPRIC2951–915 (F1) with 1 LXXLL (L1)
bound strongly to GST-PPARγ,G S T - R X R α,a n dG S T - T R α,
while ΔPRIC295840–1815 (F2) bound strongly to GST-PPARα,
GST-CAR, and GST-ERα. In general, F1 and F2 bound
more avidly than F3 to these receptors. Although PRIC295
fragments F1 and F2 bound to PPARα, surprisingly, there
was no perceptible interaction of this receptor with fragment
ΔPRIC2951740–2671 (F3) although F3 contains 5 LXXLLs
(Figures 2(a) and 4(b)). The relative binding levels were
digitally quantiﬁed (Supplementary Figure 3). These obser-
vations suggest that PRIC295 might exert a role in mediating
the transcription of target genes of several members of
the nuclear receptor superfamily. Since diﬀerent nuclear
receptorsexhibiteddiﬀerentaﬃnitiesforinteractingwiththe
3d i ﬀerent fragments of PRIC295, it is possible that diﬀerent
LXXLL motifs may determine the binding to a given nuclear
receptor. In this regard, fragment 1 (F1) which has only one
LXXLL (L1) may be important biologically as this fragment
binds more readily than the other two fragments. Additional
studies are needed to modify this ﬁrst LXXLL and selected
others for binding speciﬁcity.
3.5. PRIC295 Enhances PPARα,P P A R γ,a n dE R α-Mediated
Transcription in Mammalian Cells. In order to examine the
functional relevance of the interaction between PRIC295
and nuclear receptor proteins, we transiently coexpressed
PRIC295 with pCMX-PPARα/pCMX-RXRα (Figure 5(a)),
with pCMX-PPARγ/pCMX-RXRα (Figure 5(b)), or with
pcDNA-ERα (Figure 5(c)) in HeLa cells. These cells were
concurrently transfected with luciferase reporters pGL3-
3xPPRE-LUC for PPARα and PPARγ, or pGL3-3xERE-LUC
for ERα in order to measure the ability of PRIC295 to trans-
activate receptor-mediated transcription. PRIC295 clearly
increased the transcriptional activation of the luciferase
reporter gene in a ligand-dependent manner when cotrans-
fected with pCMX-PPARα, pCMX-PPARγ, or pcDNA-ERα
(Figures 5(a)–5(c)). PRIC295 also enhanced PPARα/RXRα-
mediated transcriptional activation of pGL3-3xPPRE-LUC
in a dose-dependent manner (Figure 5(d)). PRIC295 also
enhanced PPARα/RXRα-mediated transcription in the pres-
ence of the RXRα ligand 9-cis-retinoic acid (Supplementary
Figure 4). These results conﬁrm that PRIC295 functions as a
coactivator for nuclear receptors PPARα,P P A R γ,a n dE R α.
To further conﬁrm the transactivational activity of
PRIC295, a Gal4-binding assay was performed using
the yeast Gal4-DBD fused to the PRIC295 fragments,
ΔPRIC2951–915 (F1), ΔPRIC295840–1815 (F2), or
ΔPRIC2951740–2671 (F3). These chimeric proteins also
showed the ability to signiﬁcantly enhance transcription of
the luciferase reporter under the direction of the thymidine
kinase promoter fused to the c-terminal of Gal4. Cells
transfected with the chimeric PRIC295-F1 fragment showed
a statistically signiﬁcant (P-value = .000748 for Gal4-
DBD-F1 and .001733 for Gal4-DBD-F2) increase in relative
luciferase activity as compared to cells transfected with only
the Gal4-DBD (Figure 6). Gal4-DBD-F3 exhibited only a
modest increase in the activity (not illustrated). These data
clearly demonstrate the activity of PRIC295 as a coactivatorPPAR Research 7
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Figure 4: PRIC295 interactions with nuclear receptors. (a) In vitro interaction of radiolabeled full-length PRIC295 with nuclear receptors
PPARα,R X R α,P P A R γ,T R α,C A R ,a n dE R α. PRIC295 was radiolabeled using 35S-methionine (Perkin Elmer) and incubated with each
shown receptor fusion protein in GST-pulldown assay. (−) minus indicates in vitro binding interaction in the absence of cognate ligand
and (+) plus indicates the presence of receptor-speciﬁc ligand during the in vitro binding interaction. Ligands used: Wy-14,643 for PPARα;
9-cis-retinoic acid for RXRα; rosiglitazone for PPARγ; triiodothyronine (T3)TRα; 1,4-Bis[2-(3,5-dichloropyridyloxy)]benzene (TCPOBOP)
for CAR; 17-β-estradiol for ERα. All ligands were used at a concentration of 100μM. (b) Interaction of radiolabeled PRIC295 fragments
ΔPRIC2951–915 (F1), ΔPRIC295840–1815 (F2), and ΔPRIC2951740–2671 (F3) with GST-fusion nuclear receptor proteins. Loading for each lane
is indicated at the base of each panel. Lane 1 input; lane 2 GST alone without ligand; lane 3 GST alone with receptor-speciﬁc ligand; lane 4
GST-receptor fusion in the absence ligand; lane 5 in the presence of receptor-speciﬁc ligand. All ligands used are as previously described in
(a).
protein though the exact mechanism by which PRIC295
exerts this inﬂuence is presently unclear.
3.6. PRIC295 Binding Partners. We have previously demon-
strated that coactivator-binding protein PIMT (NCoA6IP)
interacts with PRIP (ASC-2/NCoA6), CBP, p300, and Med1
to presumably form a PIMT complex [62]. PRIP/ASC-2
also interacts with other cofactors to form a steady complex
described as ASCOM (for ASC-2 complex) [68]. ASCOM
contains histone H3-lysine-4 (H3LK4) methyltransferase
MLL3 or its paralogue MLL4 [68]. Interaction between
ASCOM and the ATPase-dependent chromatin remodeling
complex Swi/Snf have also been demonstrated and these
interactions promote the binding of these complexes to
nuclear receptor target genes [69]. Since coactivator and
coactivator-associated protein interactions are being recog-
nized with increasing frequency, we decided to investigate
whether PRIC295 associates with other cofactors. For this8 PPAR Research
0
5
10
15
20
25
×10−3
R
e
l
a
t
i
v
e
l
u
c
i
f
e
r
a
s
e
a
c
t
i
v
i
t
y PPARα
∗
∗
CMV-RL − ++++++
pGL3 − + −−−−−
3x-PPRE − ++++++
PPARα −−−−+++
RXRα −−−+ − ++
PRIC295 −−+ −−−+
(a)
0
2
4
6
8
10
12
14
16
×10−2
R
e
l
a
t
i
v
e
l
u
c
i
f
e
r
a
s
e
a
c
t
i
v
i
t
y PPARγ
∗
∗
CMV-RL − ++++++
pGL3 − + −−−−−
3x-PPRE − ++++++
PPARγ −−−−+++
RXRα −−−+ − ++
PRIC295 −−+ −−−+
(b)
0
1
2
3
4
5
6
7
×10−2
R
e
l
a
t
i
v
e
l
u
c
i
f
e
r
a
s
e
a
c
t
i
v
i
t
y
ERα
∗
∗
CMV-RL − ++++
pGL3 − + −−−
3x-ERE − ++++
ERα −− − ++
PRIC295 −− + − +
No ligand
With ligand
∗ P-value <. 05
(c)
0
5
10
15
20
25
30
35
×10−3
R
e
l
a
t
i
v
e
l
u
c
i
f
e
r
a
s
e
a
c
t
i
v
i
t
y
PPARα
CMV-RL − ++++++
pGL3 − + −−−−−
3x-PPRE − ++++++
PPARα −−+++++
RXRα −−+++++
PRIC295 −−− 10ng 25ng 50ng 100ng
No ligand
With ligand
∗ P-value <. 05
(d)
Figure 5: PRIC295 functions as a transcriptional coactivator for nuclear receptors. Data are shown for PPARα (a), PPARγ (b), and ERα (c).
pGL3-3xPPRE-LUC was used as a reporter for PPARα and PPARγ whereas 3xERE was used as reporter for ERα. HeLa cells were transfected
with 100ng of pcDNA-PRIC295, pCMX-PPARα, pCMX-pCMX-PPARγ, pCMX-ERα, pCMX-RXRα, pGL3-3xPPRE-LUC (or empty pGL3-
LUC vector), and 50ng of CMV-RL plasmid as indicated (+ or −). Each column shown is the mean relative luciferase unit value for triplicate
experiments. Open bar represents activity in the absence and dark bar in the presence of respective ligand (see Figure 4). All experiments
were normalized against the expression of Renilla luciferase (CMV-RL) as an internal control. Statistical signiﬁcance (P-value) is indicated
at the base of the panel and calculated by comparing transfected groups marked with an ∗. (d) Transcriptional activation of PPARα with the
addition of the increasing amounts of PRIC295. All other plasmids were transfected using the same amounts indicated above.
purpose, we chose to use ΔPRIC295840–1815 (F2) region
fused to GST at the N-terminus of the protein to aﬃnity
pulldown potential PRIC295 binding partners from rat
liver nuclear extracts (Figure 7(a)). PRIC295-F2 was chosen
because this fragment with 4 LXXLLs generally bound to
all nuclear receptors analyzed in this study, and also we
could not successfully express full length PRIC295 as GST-
fusion protein. MALDI-TOF mass spectrographic analysis of
selected PRIC295 F2 fragment bound peptides (Figure 7(a))
resolved by SDS-PAGE revealed the presence of PRIC285
[Q9BYK8][33],Med12L[Q86YW9],Med24[Q99K74][60],
PRMT1 [Q63009] [70], C/EBPβ [P17676] [71], Med20
[Q9H944] [72], and ZNRD1 [Q6MFY5] [73] among others
(Figure 7(b)). To conﬁrm some of these potential interac-
tions, we performed immunoblot analysis for the presence of
PPARα, Med24, and Med1 in the ciproﬁbrate bound protein
complex (Figure 7(a)). These immunoblots established the
presence of Med24 and Med1 among the proteins pulled
down using ciproﬁbrate-Sepharose slurry that appear to
form PRIC295 complex (PRIC295COM).PPAR Research 9
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Figure 6: PRIC295 functions as a coactivator protein in Gal4-binding assay. Transfection of chimeric Gal4-DBD-PRIC295-F1(E) or Gal4-
DBD-PRIC295-F2(F) signiﬁcantly enhanced transcription of the luciferase reporter gene. Transfection of chimeric Gal4-DBD-PRIC295-F3
did not signiﬁcantly enhance the transcription of the luciferase reporter (F3; not illustrated). HeLa cells were transfected with 100ng of pM-
ΔPRIC2951–915 (F1) (a), pM-ΔPRIC295840–1815 (F2) (b), Gal4-TK-Luc and 50ng of CMV-RL as indicated (+ or −). Each column shown is
the mean relative luciferase unit value for triplicate experiments. Statistical signiﬁcance was calculated by comparison of transfected groups
marked with an ∗.
3.7. PRIC295 Localizes to the Nucleus and Interaction between
PRIC295 and PPAR, Med24, and Med1 in Intact Cells.
To conﬁrm the subcellular localization of PRIC295,
pcDNA-PRIC295-3xFLAG was transfected into HeLa cells.
Immunoﬂuorescence microscopy revealed the nuclear
localization of FLAG-tagged PRIC295 (Figure 8(a);p a n e l
PRIC295-3xFLAG). We also cotransfected these cells
with pCMX-PPARα and using anti-PPARα antibodies we
conﬁrmed the expression of this receptor in the nucleus
(Figure 8(a); panel PPARα). When PRIC295 and PPARα
images were merged most nuclei were colored yellow
indicating a high degree of overlap in these cells that express
both proteins (Figure 8(a); merged image) but further high
resolution studies are needed to determine if these two
proteins are colocalized in the nucleus. Analysis of several
cells indicated that some cells were expressing PRIC295
while others only PPARα (Figure 8(a); one red and one green
nucleus in addition to several yellow colored nuclei). DAPI
was used to stain all nuclei (Figure 8(a), DAPI).
Weusedimmunoprecipitationfollowedbyimmunoblot-
ting to establish the in vivo interaction of PRIC295 with
PPARα, Med24, and Med1 (Figure 8(b)). For this purpose,
we transfected cells with PRIC295-3xFLAG and immuno-
precipitated with FLAG antibodies and immunoblotted the
precipitates with antibodies against PPARα, Med24, and
Med1 (Figure 8(b)). Clearly, this approach established the
presence of coimmunoprecipitated PPARα, Med24, and
Med1 (Figure 8(b)). These observations demonstrate that
PRIC295 interacts in vivo not only with PPARα but also
with two members of the Mediator complex in living cells.
Further studies will be necessary to analyze nuclear proteins
that bind to all three PRIC295 fragments, F1, F2, and F3, to
fully delineate the PRIC295COM.
3.8. GST-Pulldown to Establish PRIC295 Interaction with
Med1 and Med 24 In Vitro. Further experimentation was
performed to conﬁrm the interaction of PRIC295 with
Mediator complex proteins Med1 and Med24 in vitro
(Figures 9(a)–9(c)). In vitro translated and radiolabeled
full-length PRIC295 was allowed to interact with GST-
Med1 fragments (Figure 9(a)). Fragments covering Med1
aa 1–740 (not shown), 740–860, 860–980, 980–1055, 1055–
1130, 1130–1250, 1250–1370, and 1370–1470 failed to bind
with full-length PRIC295 (Figure 9(a)). However, PRIC295
bound strongly with a fragment from the C-terminal of
Med1 containing amino acids 1470–1570 (Figure 9(a)).
Coomassie-stained GST-Med1 fusion proteins used in these
assays are shown in Supplementary Figure 5. Analysis of
this region of Med1 showed a lack of any known conserved
domains or binding sites. This Med1 fragment is devoid of
any LXXLL motif. In order to ascertain the region of the
PRIC295 that binds to Med1 aa 1470–1570, GST-pulldowns
were performed using in vitro translated PRIC295 fragments
F1, F2, and F3 and found that F1 interacts strongly with
Med1 but the other PRIC295 fragments revealed minimal
binding (Figure 9(b)). Finally, GST-pulldowns also showed
that PRIC295 interacts with Med24 (Figure 9(c)).
During the past 15 years, several proteins have been
identiﬁed which interact with PPARs and other nuclear10 PPAR Research
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Figure 7: PRIC295-interacting proteins. (a) PRIC295-interacting proteins were isolated using GST-ΔPRIC295840–1815 (F2) (pGEX-
ΔPRIC295840–1815) to pull down interacting proteins from rat liver nuclear extract. Selected bands (lane 2-BP; arrows) were excised from the
4–20% Tris-HCl gel and digested with trypsin to release peptide fragments. (b) Peptide fragments derived from excised bands were subjected
to MALDI-TOF analysis. Proteins matching the identities with peptide fragments are shown with some matching peptide sequences, m/z
ratios, and accession numbers. In (a), immunoblotting of ciproﬁbrate-binding protein complex reveals the presence of PPARα (lane 3),
Med24/TRAP100 (lane 4), and Med1 (lane 5).
receptors and serve as transcription cofactors/coregulators
[18, 55, 74]. We have been using the MALDI-TOF approach
to identify and characterize PPARα or its ligand binding
proteins referred to as PRIC complex [33, 34]. Using this
mass spectrography-based technique, we now report the
identiﬁcation of a novel coactivator, PRIC295. PRIC295
revealed a strong, ligand-dependent interaction not only
withPPARα,butwithseveralothernuclearreceptorproteins.
Of considerable interest is that this protein contains several
LXXLL and HEAT repeat motifs that appear to be important
in protein-protein interactions and in transcription [67].
This may indicate that PRIC295 has a role in mediating
the transcription of target genes for several members of the
nuclear receptor superfamily, though further investigation of
this interaction and its role with those receptor proteins in
vivo is warranted.PPAR Research 11
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Figure 8: Intracellular localization of PRIC295. (a) Immunoﬂuorescence microscopy to visualize intracellular localization of PRIC295-
3xFLAG and PPARα in HeLa cancer cells after transfection with pcDNA-PRIC295-3xFLAG and pCMX-PPARα. Anti-FLAG M2 monoclonal
antibody was used for PRIC295-3xFLAG (green color), and anti-PPARα antibody was used to stain PPARα (red color). DAPI nuclear stain is
for the visualization of cells in the ﬁeld. Merged image of PRIC295-3xFLAG (green) and PPARα (red) reveals yellow coloration of nuclei that
coexpress both proteins. The presence of a green and red cell in the merged panel is an indication that these cells are not likely transfected
withbothplasmids.(b)ImmunoprecipitationdatashowingpuriﬁedPRIC295-3xFLAGproteinandcoimmunoprecipitatedproteinsPPARα,
Med24/TRAP100, and Med1. Cells were transfected with pcDNA-PRIC295-3xFLAG only.
This study also utilized MALDI-TOF procedures to deli-
neate PRIC295 binding protein complex (PRIC295COM).
Analysis revealed PRIC295 binding proteins that included
PRIC285, Med12L, Med20, and Med24 suggesting that
PRIC295 plays a potentially important role in transcription.
For example, it should be noted that PRIC285 contains
a UvrD helicase motif and has been previously shown
to enhance transcriptional activation mediated by PPARα
[33]. The association of PRIC295 with Med12L, a putative
homologue of Med12 subunit of Mediator complex, and
with Med1, Med20, and Med24, which are members of the
Mediator complex suggests that PRIC295 may be involved as
a platform protein in the formation of the large transcription
complex [33, 34, 75, 76]. While Med1 has been studied
extensively (see [77]; Viswakarma et al., PPAR Research
in press) less is known about Med24 and Med20 [77].
Med24 was initially identiﬁed as a cofactor important for
mediating transcription by thyroid hormone and vitamin
D receptors which interacts with and localizes together
with Med1/TRAP220 [60]. Med24 may also have additional
r o l e si ng e n er e g u l a t i o no u t s i d eo fi t sr o l ea sam e m b e r
of the Mediator complex [78]. Med20 was ﬁrst identiﬁed
as a human homologue of the Drosophila TRF-proximal
protein (hTRFP) and was shown to be able to enhance the
transcriptional activity of RNA Pol II [72]. Med20, together
with Mediator complex subunits Med8 and Med18 plays an
important role in the proper folding and formation of one
of the subunits of the Mediator complex [79]. PRMT1 is an
argininemethyltransferasewhichisidentiﬁedinthecomplex
of PRIC295-interacting proteins. PRMT1 was identiﬁed by
its interaction with the TIS21 and BTG1 proteins and has
been shown to have important roles in RNA processing
and transcription [70, 80]. PRMT1 potentiates the activity
of PGC-1α, a known coactivator of PPARs [81]. The role
of PRMT1 in RNA processing and transcription has been
shown to be important part in mediating viral infection
[82]. C/EBPβ is a transcription factor that is known to
be involved in processes mediated by PPARs including
adipogenesis and the induction of endoplasmic reticulum
stress [71, 83, 84]. In this study, we have identiﬁed C/EBPβ
in the complex of proteins interacting with PRIC295. Zinc
ribbon domain-containing 1 (ZNRD1) was also among the
complex of PRIC295-interacting proteins. ZNRD1 has a role
in regulating ERCC1 and Bcl-2 which are important in12 PPAR Research
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Figure 9: PRIC295 interacts with Med1. (a) In vitro translated and radiolabeled PRIC295 protein interacts with the known PPARα
coactivator, Med1, as assessed by GST-pulldown approach using GST-fusion protein fragments of the PBP protein. Interaction between
PRIC295 and GST-ΔPBP61470–1570 appears robust. (b) GST-pulldown of radiolabeled ΔPRIC2951–915 (F1), ΔPRIC295840–1815 (F2), and
ΔPRIC2951740–2671 (F3), respectively, using GST-ΔPBP
1470–1570 showing a strong binding interaction occurring between ΔPRIC2951–915 (F1)
and GST-ΔPBP
1470–1570.
cancer progression though the mechanism by which it does
this is presently unclear [85]. ZNRD1 also appears to have an
inﬂuence in the progression of HIV infection [86].
Evidence suggests that certain coactivators are essen-
tial for the eﬀective transcriptional activation of PPARα
target genes [57, 87]. Conditional deletion in the mouse
liver of the coactivator MED1 results in impaired liver
regeneration following partial hepatectomy [57]. Absence of
Med1 results in the abrogation of PPARα ligand induced
pleiotropic responses including hepatocarcinogenesis [57,
87]. Deﬁciency of Med1 also prevents acetaminophen-
induced hepatotoxicity [87]. On the other hand, absence
of SRC-1, SRC-2, and SRC-3 had no eﬀect on PPARα
signaling (see [88]; Viswakarma et al., PPAR Research in
press). Med1 is essential for the interaction of the activated
PPARα/RXRα heterodimer with RNA polymerase II and the
basal transcription machinery of the cell [89]. In addition,
germ-line deletion of Med1 results in embryonic lethality
illustrating the important roles that coactivator proteins may
be playing in other tissues [90–92]. Given this information,
the interaction of PRIC295 with Med1, Med24, and some
other members of the Mediator complex of proteins is of
particular interest
4. Conclusions
In the recent past, many new coactivator proteins that are
involvedinthetranscriptionalregulationoftheexpressionof
PPARα target genes have been discovered and studied. These
coactivatorsgrantawaytoregulatethetranscriptionalability
of PPARα and other nuclear receptors in a tissue and cell-
speciﬁc manner. Our studies show that PRIC295 is a nuclear
receptor coactivator which interacts with PPARα and several
other nuclear receptors and may play a larger role in the
transcription of target genes through nuclear receptors. The
association of proteins such as Med1, Med24, and Med20,
the members of Mediator complex with PRIC295 suggests
the existence in vivo of a complex of proteins designated
PRIC295COM.
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